Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Global Longlife Hospital & Research 3-Year ROIIC %?
Global Longlife Hospital & ResearchBOM:543520 +4.07%37 3-Year ROIIC % is 4.63 as of Mar. 2026, which is 256% above its 10-year median of 1.30. GuruFocus rates BOM:543520 with a GF Score™ of 37/100 and a GF Value™ of ₹1.37 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 618 Healthcare Providers & Services companies, Global Longlife Hospital & Research ranks better than 51.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Global Longlife Hospital & Research's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 4.63%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
BOM:543520's 3-Year ROIIC % is ranked better than 51.46% of 618
companies
in the Healthcare Providers & Services industry
Industry Median: 3.605
vs BOM:543520: 4.63
Global Longlife Hospital & Research (BOM:543520) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Global Longlife Hospital & Research 3-Year ROIIC % Related Terms
Global Longlife Hospital & Research 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Longlife Hospital & Research 3-Year ROIIC % Chart
BOM:543520 vs HCA, THC, EHC: 3-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, Global Longlife Hospital & Research's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Longlife Hospital & Research 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Global Longlife Hospital & Research's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Global Longlife Hospital & Research's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -9.929 (Mar. 2026) - 19.5781741 (Mar. 2023) )
/
( 67.443 (Mar. 2026) - 704.819 (Mar. 2023) )
=
-29.5071741
/
-637.376
=
4.63%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Global Longlife Hospital & Research (BOM:543520) has a 3-Year ROIIC % of 4.63 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Global Longlife Hospital & Research and its competitors. This is 256% above median its historical median of 1.30. According to the industry distribution chart, Global Longlife Hospital & Research ranks #300 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 48.5%.
Is Global Longlife Hospital & Research's 3-Year ROIIC % too high?
Global Longlife Hospital & Research's current 3-Year ROIIC % of 4.63 is 256% above median its 10-year median of 1.30. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.61. Global Longlife Hospital & Research's value of 4.63 is 28.4% above this industry median. Based on the distribution chart, Global Longlife Hospital & Research ranks #300 out of 618 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Global Longlife Hospital & Research has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Global Longlife Hospital & Research's 3-Year ROIIC % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Global Longlife Hospital & Research ranks #300 out of 618 companies for 3-Year ROIIC %. This puts Global Longlife Hospital & Research in the upper half of its industry. The industry median 3-Year ROIIC % is 3.61. Global Longlife Hospital & Research's value of 4.63 is 28.4% above this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 3.61, Global Longlife Hospital & Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.61, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Global Longlife Hospital & Research's current 3-Year ROIIC % of 4.63 is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Global Longlife Hospital & Research and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Longlife Hospital & Research's current 3-Year ROIIC % is 4.63, which is 256% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Longlife Hospital & Research stock overvalued right now?
Based on GuruFocus' analysis, Global Longlife Hospital & Research (BOM:543520) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.37, compared to a current price of ₹12.27 — trading 795.6% above its estimated fair value. The current 3-Year ROIIC % is 4.63, which is 256% above median its 10-year median of 1.30 and 28.4% above the Healthcare Providers & Services industry median of 3.61. Global Longlife Hospital & Research's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Global Longlife Hospital & Research (BOM:543520), the current 3-Year ROIIC % is 4.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Global Longlife Hospital & Research (BOM:543520) Overvalued in 2026?
Based on GuruFocus' analysis, Global Longlife Hospital & Research stock appears to be overvalued.
The current stock price of ₹12.27 is trading 795.6% above its estimated GF Value™ of ₹1.37.
GuruFocus considers Global Longlife Hospital & Research to be Significantly Overvalued.
Key valuation signals for BOM:543520:
3-Year ROIIC %: 4.63 (256% above median its 10-year median of 1.30)
GF Value™: ₹1.37 vs. price of ₹12.27 (795.6% above fair value)
Industry Position: 28.4% above the Healthcare Providers & Services median (#300 of 618)
No single metric tells the full story. See the BOM:543520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Global Longlife Hospital & Research Ltd is Multispecialty Hospital providing Medical & Allied Services. The company operates in the single segment i.e. Health Care and Hospital. Its services are Medical, Surgical, Radiology, Pathology, and Other Services.
37GF Score
Get the complete analysis for BOM:543520
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543520 has been successfully added to your 
